Abstract
Epidemiological studies have demonstrated that the use of methamphetamine (METH), a sympathomimetic stimulant, is particularly common among patients infected with HIV. In vitro studies have determined that METH enhances HIV infection of CD4+ T cells, monocyte-derived dendritic cells, and macrophages. In addition, animal studies have also showed that METH treatment increases brain viral load of SIV-infected monkeys and promotes HIV replication and viremia in HIV/hu-CycT1 transgenic mice. However, the mechanisms (s) of METH actions on HIV remain to be determined. In this study, we investigated the impact of METH on intracellular restriction factors against HIV and SIV. We demonstrated that METH treatment of human blood mononuclear phagocytes significantly affected the expression of anti-HIV microRNAs and several key elements (RIG-I, IRF-3/5, SOCS-2, 3 and PIAS-1, 3, X, Y) in the type I IFN pathway. The suppression of these innate restriction factors was associated with a reduced production of type I IFNs and the enhancement of HIV or SIV infection of macrophages. These findings indicate that METH use impairs intracellular innate antiviral mechanism(s) in macrophages, contributing to cell susceptibility to the acquired immune deficiency syndrome (AIDS) virus infection.
Keywords: HIV, Interferon, Intracellular restriction factors, Macrophages, METH, microRNAs, SIV, Interferon regulatory factor, Interferon regulatory, IFN, JAK-STAT.
Current HIV Research
Title:Modulation of Intracellular Restriction Factors Contributes to Methamphetamine- Mediated Enhancement of Acquired Immune Deficiency Syndrome Virus Infection of Macrophages
Volume: 10 Issue: 5
Author(s): Xu Wang, Yizhong Wang, Li Ye, Jieliang Li, Yu Zhou, Sinem Sakarcan and Wenzhe Ho
Affiliation:
Keywords: HIV, Interferon, Intracellular restriction factors, Macrophages, METH, microRNAs, SIV, Interferon regulatory factor, Interferon regulatory, IFN, JAK-STAT.
Abstract: Epidemiological studies have demonstrated that the use of methamphetamine (METH), a sympathomimetic stimulant, is particularly common among patients infected with HIV. In vitro studies have determined that METH enhances HIV infection of CD4+ T cells, monocyte-derived dendritic cells, and macrophages. In addition, animal studies have also showed that METH treatment increases brain viral load of SIV-infected monkeys and promotes HIV replication and viremia in HIV/hu-CycT1 transgenic mice. However, the mechanisms (s) of METH actions on HIV remain to be determined. In this study, we investigated the impact of METH on intracellular restriction factors against HIV and SIV. We demonstrated that METH treatment of human blood mononuclear phagocytes significantly affected the expression of anti-HIV microRNAs and several key elements (RIG-I, IRF-3/5, SOCS-2, 3 and PIAS-1, 3, X, Y) in the type I IFN pathway. The suppression of these innate restriction factors was associated with a reduced production of type I IFNs and the enhancement of HIV or SIV infection of macrophages. These findings indicate that METH use impairs intracellular innate antiviral mechanism(s) in macrophages, contributing to cell susceptibility to the acquired immune deficiency syndrome (AIDS) virus infection.
Export Options
About this article
Cite this article as:
Wang Xu, Wang Yizhong, Ye Li, Li Jieliang, Zhou Yu, Sakarcan Sinem and Ho Wenzhe, Modulation of Intracellular Restriction Factors Contributes to Methamphetamine- Mediated Enhancement of Acquired Immune Deficiency Syndrome Virus Infection of Macrophages, Current HIV Research 2012; 10 (5) . https://dx.doi.org/10.2174/157016212802138797
DOI https://dx.doi.org/10.2174/157016212802138797 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in people living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiaging Therapy: A Novel Target for Antilipolytic Drugs
Mini-Reviews in Medicinal Chemistry Is Red Meat Required for the Prevention of Iron Deficiency Among Children and Adolescents?
Current Pediatric Reviews The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design ATP-Sensitive K+ Channels: Current and Putative Target for the Prevention and Treatment of Cardiovascular Diseases
Vascular Disease Prevention (Discontinued) Skeletal Myoblasts for Heart Regeneration and Repair: State of the Art and Perspectives on the Mechanisms for Functional Cardiac Benefits
Current Pharmaceutical Design Animal Models of Atherosclerosis Progression: Current Concepts
Current Drug Targets - Cardiovascular & Hematological Disorders Rosuvastatin Ameliorates Obesity and Proteinuria in Zucker Diabetic Fatty Rats
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Experimental Models of Abdominal Aortic Aneurysms: An Overview
Current Pharmaceutical Design Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases
Current Pharmacogenomics Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus
Current Cardiology Reviews MicroRNAs Patents: The Road From Bench to Bedsides for Cancer Treatment
Recent Patents on DNA & Gene Sequences Improving Adherence to Antipsychotic Pharmacotherapy
Current Clinical Pharmacology Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Histone Deacetylase Inhibitors and Colorectal Cancer: what is new?
Anti-Cancer Agents in Medicinal Chemistry Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?
Current Pharmaceutical Design Reprogrammed Metabolism of Cancer Cells as a Potential Therapeutic Target
Current Pharmaceutical Design New Chemotherapeutic Strategies Against Malaria, Leishmaniasis and Trypanosomiases
Current Medicinal Chemistry Trick-or-Treat: Dietary Lipids and Host Resistance to Infectious Disease
Mini-Reviews in Medicinal Chemistry Recent Advances in the Synthesis and Development of Curcumin, its Combinations and Formulations and Curcumin-like Compounds as Anti-infective Agents
Current Medicinal Chemistry Reversal of Cardiac Iron Loading and Dysfunction in Thalassemic Mice by Curcuminoids
Medicinal Chemistry